CRMD
CorMedix Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| DefenCath sales | $97.5M | Q1 2026 | — |
| Melinta portfolio revenue | $29.9M | Q1 2026 | — |
| adjusted EBITDA non-GAAP | $70M | Q1 2026 call | — |
|
|
|||
| RepSPECT study fungal-free survival at day 90 (REZZAYO) | 60.7% | ReSPECT Phase III study call | — |
| RepSPECT study fungal-free survival at day 90 (standard antifungal regimen) | 59% | ReSPECT Phase III study call | — |
| Pro Forma 2025 revenue non-GAAP | $401.3M | full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRMD
this stock
CorMedix Inc.
|
$659.00M | -27.8% | +617.0% | 3.9 | 19.0% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRMD | -4.0% | -4.2% | +19.8% | +7.0% | -27.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -5.4% | -8.3% | +10.8% | +5.9% | -38.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.